UBS AM’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-237,506
| Closed | -$40.9M | – | 2943 |
|
|
2021
Q3 | $40.9M | Buy |
237,506
+9,617
| +4% | +$1.26M | 0.02% | 684 |
|
|
2021
Q2 | $28.6M | Buy |
227,889
+37,135
| +19% | +$4.68M | 0.01% | 793 |
|
|
2021
Q1 | $25.9M | Sell |
190,754
-47,995
| -20% | -$6.2M | 0.01% | 794 |
|
|
2020
Q4 | $30.5M | Buy |
238,749
+5,426
| +2% | +$636K | 0.01% | 736 |
|
|
2020
Q3 | $26.3M | Sell |
233,323
-28,301
| -11% | -$2.82M | 0.01% | 695 |
|
|
2020
Q2 | $24.9M | Buy |
261,624
+4,069
| +2% | +$392K | 0.02% | 680 |
|
|
2020
Q1 | $23.1M | Sell |
257,555
-89,297
| -26% | -$6.94M | 0.02% | 634 |
|
|
2019
Q4 | $18.4M | Buy |
346,852
+31,889
| +10% | +$1.45M | 0.01% | 797 |
|
|
2019
Q3 | $12.4M | Sell |
314,963
-35,986
| -10% | -$1.56M | 0.01% | 887 |
|
|
2019
Q2 | $14.4M | Buy |
350,949
+5,445
| +2% | +$225K | 0.01% | 845 |
|
|
2019
Q1 | $16.1M | Sell |
345,504
-4,955
| -1% | -$218K | 0.01% | 797 |
|
|
2018
Q4 | $15.3M | Buy |
350,459
+67,176
| +24% | +$3.36M | 0.01% | 764 |
|
|
2018
Q3 | $16.2M | Sell |
283,283
-44,797
| -14% | -$2.2M | 0.01% | 815 |
|
|
2018
Q2 | $15.9M | Sell |
328,080
-84,230
| -20% | -$3.07M | 0.01% | 825 |
|
|
2018
Q1 | $16.1M | Sell |
412,310
-23,053
| -5% | -$980K | 0.01% | 807 |
|
|
2017
Q4 | $18.5M | Buy |
435,363
+109,913
| +34% | +$4.12M | 0.02% | 768 |
|
|
2017
Q3 | $12.1M | Buy |
325,450
+4,718
| +1% | +$164K | 0.01% | 859 |
|
|
2017
Q2 | $9.75M | Buy |
+320,732
| New | +$9.29M | 0.01% | 908 |
|
|
2016
Q4 | – | Sell |
-10,600
| Closed | -$384K | – | 2735 |
|
|
2016
Q3 | $384K | Hold |
10,600
| – | – | ﹤0.01% | 2133 |
|
|
2016
Q2 | $360K | Hold |
10,600
| – | – | ﹤0.01% | 2136 |
|
|
2016
Q1 | $280K | Sell |
10,600
-162,624
| -94% | -$4.73M | ﹤0.01% | 2252 |
|
|
2015
Q4 | $8.45M | Buy |
173,224
+52,327
| +43% | +$1.88M | 0.01% | 902 |
|
|
2015
Q3 | $3.01M | Buy |
120,897
+5,105
| +4% | +$153K | ﹤0.01% | 1252 |
|
|
2015
Q2 | $3.66M | Buy |
115,792
+5,092
| +5% | +$164K | ﹤0.01% | 1150 |
|
|
2015
Q1 | $4.21M | Sell |
110,700
-2,700
| -2% | -$107K | ﹤0.01% | 1092 |
|
|
2014
Q4 | $4.42M | Sell |
113,400
-2,300
| -2% | -$80.2K | ﹤0.01% | 1065 |
|
|
2014
Q3 | $3.5M | Sell |
115,700
-5,100
| -4% | -$144K | ﹤0.01% | 1121 |
|
|
2014
Q2 | $4.1M | Buy |
120,800
+56,200
| +87% | +$1.88M | ﹤0.01% | 1087 |
|
|
2014
Q1 | $2.23M | Sell |
64,600
-500
| -0.8% | -$22.6K | ﹤0.01% | 1276 |
|
|
2013
Q4 | $2.58M | Buy |
+65,100
| New | +$1.57M | ﹤0.01% | 1176 |
|
UBS AM's XLRN Position: Q4 2021 in Review
UBS AM sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 237,506 shares — an estimated $40.9M sold.
UBS AM first reported a position in XLRN in Q4 2013 and held it in 30 quarters. The position peaked at $40.9M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- UBS AM reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- UBS AM sold 237,506 Acceleron Pharma shares in Q4 2021, an estimated $40.9M.
- UBS AM first reported a position in Acceleron Pharma in Q4 2013 and held it in 30 quarters.
- UBS AM's Acceleron Pharma position peaked at $40.9M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.